Capitol Hill News In Brief
This article was originally published in The Gray Sheet
Senate passage sends trade promotion authority bill to President Obama for his signature; House “21st Century Cures” legislation gains 230 co-sponsors in the House; Senate Finance panel marks up disposable medical technologies bill.
You may also be interested in...
The targeted FDA Device Accountability Act mirrors select device sections of the House 21st Century Cures legislation seeking to strengthen the use of "least-burdensome" provisions, allow use of centralized IRBs for device trials and refining standards for diagnostic CLIA waivers.
Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers for 2023, and index-linked increases thereafter.